Efficacy Study of Oxygenated Glycerol Triesters to Treat Xerostomia

This study has been completed.
Sponsor:
Information provided by:
Laboratoires CARILENE
ClinicalTrials.gov Identifier:
NCT00332618
First received: May 31, 2006
Last updated: June 6, 2006
Last verified: March 2003
  Purpose

The objective of the trial was to evaluate the efficacy and clinical safety and acceptability of Oxygenated Glycerol Triesters in the relief of symptoms of xerostomia versus a reference comparator.


Condition Intervention Phase
Xerostomia
Device: OXYGENATED GLYCEROL TRIESTERS
Phase 2

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Official Title: Multicenter Controlled Parallel-Groups Trial to Evaluate the Efficacy, Safety and Acceptability of TGO Buccal Spray Versus a Saliva Substitute in the Treatment of Psychotropic Medicines-Induced Xerostomia

Resource links provided by NLM:


Further study details as provided by Laboratoires CARILENE:

Estimated Enrollment: 74
Study Start Date: September 2003
Estimated Study Completion Date: April 2004
Detailed Description:

Xerostomia is due to inadequate (hyposialia) or inexistent (asialia) saliva secretion.

There are may causes. Transitory xerostomia may occur in the presence of anxiety (stage fright, fear or dehydration). Prolonged xerostomia is most often related to a systemic disease, certain medicines or to radiotherapy of the head or neck.

Salivation depends upon the autonomic (sympathetic and parasympathetic) nervous system for its production and on the central nervous system for stimuli-dependant excretion. Substances acting on alpha an beta sympathetic receptors, whether agonists or antagonists, may induce hyposialia. Atropine, the main antagonist of the parasympathetic system, is present in many medicines used for pulmonary, ophthalmic or neurological purposes, potentially causing hyposialia. Similarly, imipramine antidepressants, phenothiazine neuroleptics, antihistamines and disopyramide predispose to the onset of hyposialia.

Xerostomia is often accompanied by buccal signs such as impaired sense of taste, halitosis and buccal ulcers and interferes with functions such as speech, chewing and swallowing. Because of reduced salivary secretion , there is a disturbance of the microbial colonization of the buccal cavity. Xerostomia has significant untoward effects on the buccal cavity and the quality of life of patients.

The basis of the treatment of xerostomia involves the use of saliva substitutes and/or saliva stimulants. Oxygenated Glycerol Triesters is neither a replacement for nor stimulant of saliva. It is a lubricant and protective solution for endobuccal spray.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • men or women over 18 years of age
  • with a diagnosis requiring the prescription of psychotropies (antidepressants, tranquilizers, etc) for more than 6 weeks
  • having received no palliative treatment for xerostomia for a minimum of the past 2 weeks
  • having xerostomia meeting the questionnaire selection criteria and the sialometer method parameters
  • patients legally competent to give their consent
  • capable of and accepting to participate in the trial and capable of and accepting to answer trial questionnaires

Exclusion Criteria:

  • combined treatments incompatible with the trial, un particular alcoholic solutions
  • diabetes, any buccal condition requiring antimicrobial treatment
  • Sjögren's syndrome or othermedical causes of xerostomia
  • current participation in other clinical trials
  • patient suffering from cancer
  • patients with allergy to or known intolerance of any of the constituents of the investigational products
  • patients treated with pilocarpine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00332618

Locations
France
Chu Hopital Des Broussailles
Cannes, France, 06000
Sponsors and Collaborators
Laboratoires CARILENE
Investigators
Study Director: YVES YT TILLET, Expertpharma WHITE TILLET Consultants
Principal Investigator: Jean Baptiste JO Orler, Psychiatrist CHU HOPITAL DES BROUSSAILLES
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00332618     History of Changes
Other Study ID Numbers: Laboratoires CARILENE
Study First Received: May 31, 2006
Last Updated: June 6, 2006
Health Authority: France: Ministry of Health
United States: Institutional Review Board

Keywords provided by Laboratoires CARILENE:
MULTICENTER
CONTROLLED
PARALLEL GROUPS

Additional relevant MeSH terms:
Xerostomia
Mouth Diseases
Salivary Gland Diseases
Stomatognathic Diseases
Glycerol
Cryoprotective Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents

ClinicalTrials.gov processed this record on October 23, 2014